Clinical presentation of cutaneous metastases is often variable. Presented case had an intriguing cutaneous metastasis of bronchogenic squamous cell carcinoma. Lesions were characterized by dermatomal pattern with milia-like papules, plaques, and nodules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/jcrt.JCRT_450_17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous squamous carcinoma with pulmonary metastasis with cavity formation successfully treated with nivolumab.
J Dermatol
January 2025
Department of Dermatology, Jichi Medical University, Tochigi, Japan.
Treatment of Cutaneous Adnexal Carcinoma With Radiotherapy: A 20-Year, Single-Institution Experience in 49 Patients.
Am J Clin Oncol
January 2025
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Objectives: Cutaneous adnexal carcinomas (CACs) are rare skin cancers with no established treatment guidelines. Given the limited data, this study aims to explore the characteristics and outcomes of patients with CAC treated with radiation therapy (RT).
Methods: Patients diagnosed with CAC between 2000 and 2020 who received RT were included.
Rare Presentation of Cutaneous Metastasis in Breast Carcinoma.
Cureus
December 2024
Surgery, All India Institute of Medical Sciences, New Delhi, IND.
Recurrence beyond the second year of diagnosis and metastasis to the skin and eyelids are rare occurrences in breast cancer. When cutaneous metastases present without local recurrence, they pose a significant diagnostic challenge. Here, we describe a case of breast cancer that recurred 16 years after the initial treatment, with the only indication of recurrence being unusual skin and eyelid lesions.
View Article and Find Full Text PDFSteatohepatitis-induced vascular niche alterations promote melanoma metastasis.
Cancer Metab
January 2025
Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany.
Background: In malignant melanoma, liver metastases significantly reduce survival, even despite highly effective new therapies. Given the increase in metabolic liver diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), this study investigated the impact of liver sinusoidal endothelial cell (LSEC)-specific alterations in MASLD/MASH on hepatic melanoma metastasis.
Methods: Mice were fed a choline-deficient L-amino acid-defined (CDAA) diet for ten weeks to induce MASH-associated liver fibrosis, or a CDAA diet or a high fat diet (HFD) for shorter periods of time to induce early steatosis-associated alterations.
Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study).
Clin Genitourin Cancer
January 2025
Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
Introduction: Enfortumab vedotin (EV) currently plays a predominant role in the evolving treatment paradigm of metastatic urothelial carcinoma (mUC). However, large-scale real-world data on EV remain limited. This multicenter retrospective study comprehensively evaluated treatment outcomes and prognostic factors of EV monotherapy for mUC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!